These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
3. Histone Lysine-to-Methionine Mutation as Anticancer Drug Target. Yang J; Qiu Q; Chen L Adv Exp Med Biol; 2021; 1283():85-96. PubMed ID: 33155140 [TBL] [Abstract][Full Text] [Related]
4. Therapeutic targeting of polycomb and BET bromodomain proteins in diffuse intrinsic pontine gliomas. Piunti A; Hashizume R; Morgan MA; Bartom ET; Horbinski CM; Marshall SA; Rendleman EJ; Ma Q; Takahashi YH; Woodfin AR; Misharin AV; Abshiru NA; Lulla RR; Saratsis AM; Kelleher NL; James CD; Shilatifard A Nat Med; 2017 Apr; 23(4):493-500. PubMed ID: 28263307 [TBL] [Abstract][Full Text] [Related]
5. Oncohistones: Hijacking the histone code. Sahu V; Lu C Annu Rev Cancer Biol; 2022 Apr; 6():293-312. PubMed ID: 36589281 [TBL] [Abstract][Full Text] [Related]
6. Mechanism of cancer: Oncohistones in action. Qiu L; Hu X; Jing Q; Zeng X; Chan KM; Han J J Genet Genomics; 2018 May; 45(5):227-236. PubMed ID: 29804713 [TBL] [Abstract][Full Text] [Related]
9. Histone Variant and Cell Context Determine H3K27M Reprogramming of the Enhancer Landscape and Oncogenic State. Nagaraja S; Quezada MA; Gillespie SM; Arzt M; Lennon JJ; Woo PJ; Hovestadt V; Kambhampati M; Filbin MG; Suva ML; Nazarian J; Monje M Mol Cell; 2019 Dec; 76(6):965-980.e12. PubMed ID: 31588023 [TBL] [Abstract][Full Text] [Related]
10. Detection of histone H3 K27M mutation and post-translational modifications in pediatric diffuse midline glioma via tissue immunohistochemistry informs diagnosis and clinical outcomes. Huang T; Garcia R; Qi J; Lulla R; Horbinski C; Behdad A; Wadhwani N; Shilatifard A; James C; Saratsis AM Oncotarget; 2018 Dec; 9(98):37112-37124. PubMed ID: 30647848 [TBL] [Abstract][Full Text] [Related]
11. Combined Targeting of Mutant p53 and Jumonji Family Histone Demethylase Augments Therapeutic Efficacy of Radiation in H3K27M DIPG. Nikolaev A; Fiveash JB; Yang ES Int J Mol Sci; 2020 Jan; 21(2):. PubMed ID: 31940975 [TBL] [Abstract][Full Text] [Related]
12. Current Murine Models and New Developments in H3K27M Diffuse Midline Gliomas. Welby JP; Kaptzan T; Wohl A; Peterson TE; Raghunathan A; Brown DA; Gupta SK; Zhang L; Daniels DJ Front Oncol; 2019; 9():92. PubMed ID: 30873381 [TBL] [Abstract][Full Text] [Related]
13. Recognition of cancer mutations in histone H3K36 by epigenetic writers and readers. Klein BJ; Krajewski K; Restrepo S; Lewis PW; Strahl BD; Kutateladze TG Epigenetics; 2018; 13(7):683-692. PubMed ID: 30045670 [TBL] [Abstract][Full Text] [Related]
14. Histone H2B Mutations in Cancer. Wan YCE; Chan KM Biomedicines; 2021 Jun; 9(6):. PubMed ID: 34205231 [TBL] [Abstract][Full Text] [Related]
15. Automethylation of PRC2 promotes H3K27 methylation and is impaired in H3K27M pediatric glioma. Lee CH; Yu JR; Granat J; SaldaƱa-Meyer R; Andrade J; LeRoy G; Jin Y; Lund P; Stafford JM; Garcia BA; Ueberheide B; Reinberg D Genes Dev; 2019 Oct; 33(19-20):1428-1440. PubMed ID: 31488577 [TBL] [Abstract][Full Text] [Related]
16. Identification of Novel RAS Signaling Therapeutic Vulnerabilities in Diffuse Intrinsic Pontine Gliomas. Koncar RF; Dey BR; Stanton AJ; Agrawal N; Wassell ML; McCarl LH; Locke AL; Sanders L; Morozova-Vaske O; Myers MI; Hamilton RL; Carcaboso AM; Kohanbash G; Hu B; Amankulor NM; Felker J; Kambhampati M; Nazarian J; Becher OJ; James CD; Hashizume R; Broniscer A; Pollack IF; Agnihotri S Cancer Res; 2019 Aug; 79(16):4026-4041. PubMed ID: 31201162 [TBL] [Abstract][Full Text] [Related]
18. The dark side of histones: genomic organization and role of oncohistones in cancer. Amatori S; Tavolaro S; Gambardella S; Fanelli M Clin Epigenetics; 2021 Apr; 13(1):71. PubMed ID: 33827674 [TBL] [Abstract][Full Text] [Related]